Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
Landos Biopharma (NASDAQ: LABP) announced that its Chairman and CEO, Josep Bassaganya-Riera, will present at the Raymond James Virtual Human Health Innovation Conference on June 21, 2021, at 2:00 PM EDT. The presentation will highlight Landos' innovative LANCE Advanced A.I. platform, which is focused on developing oral therapeutics for autoimmune diseases. The live webcast can be accessed on the company's website, and it will be archived for future viewing. Landos is advancing 17 programs targeting key immunometabolic pathways.
- None.
- None.
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.
A live webcast of the presentation will be accessible through the Investors/Media section of the Company’s website at www.landosbiopharma.com. Following the event, the webcast will be archived on the Landos website.
About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit www.landosbiopharma.com.
Contacts:
Michael K. Levitan (investors)
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com
Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@soleburytrout.com
FAQ
When will Landos Biopharma present at the Raymond James conference?
What is the focus of Landos Biopharma's presentation?
Where can I watch the Landos Biopharma presentation?
What disease areas does Landos Biopharma target?
What is the stock symbol for Landos Biopharma?
